Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults.
Wilson E, Goswami J, Baqui AH, Doreski PA, Perez-Marc G, Zaman K, Monroy J, Duncan CJA, Ujiie M, Rämet M, Pérez-Breva L, Falsey AR, Walsh EE, Dhar R, Wilson L, Du J, Ghaswalla P, Kapoor A, Lan L, Mehta S, Mithani R, Panozzo CA, Simorellis AK, Kuter BJ, Schödel F, Huang W, Reuter C, Slobod K, Stoszek SK, Shaw CA, Miller JM, Das R, Chen GL; ConquerRSV Study Group. Wilson E, et al. Among authors: kuter bj. N Engl J Med. 2023 Dec 14;389(24):2233-2244. doi: 10.1056/NEJMoa2307079. N Engl J Med. 2023. PMID: 38091530 Clinical Trial.
Neutralization of Omicron Subvariant BA.2.75 after Bivalent Vaccination.
Chalkias S, Feng J, Chen X, Zhou H, Marshall JC, Girard B, Tomassini JE, Kuter BJ, Montefiori DC, Das R. Chalkias S, et al. Among authors: kuter bj. N Engl J Med. 2022 Dec 8;387(23):2194-2196. doi: 10.1056/NEJMc2212772. Epub 2022 Nov 23. N Engl J Med. 2022. PMID: 36416761 Free PMC article. No abstract available.
Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trial.
Dixit A, Bennett R, Ali K, Griffin C, Clifford RA, Turner M, Poston R, Hautzinger K, Yeakey A, Girard B, Zhou W, Deng W, Zhou H, Schnyder Ghamloush S, Kuter BJ, Slobod K, Miller JM, Priddy F, Das R; ROVER Study Investigators. Dixit A, et al. Among authors: kuter bj. Lancet Infect Dis. 2024 Mar 19:S1473-3099(24)00101-4. doi: 10.1016/S1473-3099(24)00101-4. Online ahead of print. Lancet Infect Dis. 2024. PMID: 38518789
Safety and immunogenicity of a third dose of mRNA-1273 vaccine among cancer patients.
Giuliano A, Kuter B, Pilon-Thomas S, Whiting J, Mo Q, Leav B, Sirak B, Cubitt C, Dukes C, Isaacs-Soriano K, Kennedy K, Ball S, Dong N, Jain A, Hwu P, Lancet J. Giuliano A, et al. Cancer Commun (Lond). 2023 Jul;43(7):749-764. doi: 10.1002/cac2.12453. Epub 2023 Jun 28. Cancer Commun (Lond). 2023. PMID: 37377402 Free PMC article.
Neutralizing Antibody Response following a Third Dose of the mRNA-1273 Vaccine among Cancer Patients.
Dukes CW, Potez M, Lancet J, Kuter BJ, Whiting J, Mo Q, Leav B, Wang H, Vanas JS, Cubitt CL, Isaacs-Soriano K, Kennedy K, Rathwell J, Diaz Cobo J, O'Nan W, Sirak B, Dong N, Tan E, Hwu P, Giuliano AR, Pilon-Thomas S. Dukes CW, et al. Among authors: kuter bj. Vaccines (Basel). 2023 Dec 22;12(1):13. doi: 10.3390/vaccines12010013. Vaccines (Basel). 2023. PMID: 38250826 Free PMC article.
73 results